DEVELOPMENT OF OPTIMAL EXPERIMENTAL THERAPEUTIC REGIMENS ADMINISTRATION OF IMMOBILIZED INTERFERON α-2b

The development of optimal experimental therapeutic schemes of immobilized interferon α-2b (production of JSC «Siberian Center for Pharmacology and Biotechnology», Novosibirsk) administration was conducted in the frame of the common program of pre-clinical study. The drug being studied was administered intragastrically for 3, 5 and 7 days in the therapeutic dose (1.8 × 10⁵ IU/kg).  Experimental evaluation of immunotropic properties of immobilized interferon α-2b was carried out at in vivoexperiments in outbred CD1 male mice with using of following tests: the study of drug effect on the phagocytic activity of peritoneal leukocytes (the relative number of phagocytes and the number of bacteria which were assimilated by phagocytes were assessed); the study of drug effect on the humoral immune response (the total number of splenocytes, the relative and absolute number of antibody-forming cells and their functional activity were determined); estimation of drug effect on the cellular immune response with the using of delayed-type hypersensitivity test induced by sheep red blood cells. Based on these data we concluded that course administration of immobilized interferon α-2b in the therapeutic dose for 5 days increased phagocytosis of neutrophils and humoral immune response most effectively. Cell-mediated immune response was significantly increased after 7-fold administration of studied drug.

1. Narovlyanskiy A.N., Ershov F.I., Gintsburg A.L. In- terferons: perspective directions of research. Immunologiya – Immunology, 2013, vol 3, pp. 168–172 (in Russian).

2. Caraglia M., Marra M., Pelaia G., Maselli R., Caputi M., Marsico S. A., Abbruzzese A. Alpha-interferon and its ef-fects on signal transduction pathways. Journal of Cellular Physiology, 2005, vol. 202, pp. 323–335.

3. Yershov F.I., Kiselev O.I. Interferons and their inducers (from molecules to medicines). Moscow, GEOTAR-MED Publ., 2005. (in Russian).

4. Goodbourn S., Didcock L., Randall R.E. Interferons: cell signalling, immune modulation, anti-viral response and virus countermeasures. Journal of General Virology, 2000, vol. 81, no. 10, pp. 2341–2364.

5. Karabelsky A.V., Padkina M.V. The recombinant interferon – a long-acting. Vestnik SPbGU, 2007, vol. 3, no. 4, pp. 45–53 (in Russian).

6. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology, 2002, vol. 36, pp. 237–244.

7. Grace M., Cutler D. Pegylating IFNs at His-34 improves the in vitro antiviral activity through the JAK/STAT pathway. Antiviral Chemistry & Chemotherapy, 2004, vol. 15, no. 6, pp. 287–297.

8. Madonov P.G., Yershov K.I., Dubrovin A.V., Miroshnikov P.N., Shilova M.A., Kinsht D.N. Electron beam modification of the protein drugs to improve their pharmacological properties. Medicine and education, 2013, no. 4. URL: http://ngmu.ru/cozo/mos/article/text_full.php?id=1115 (in Russian).

9. Dygay A.M., Artamonov A.V., Bekarev A.A., Zhdanov V.V., Zyuzkov G.N., Madonov P.G., Udut V.V. Nanotechnology in pharmacology. Moscow, RAMN Publ., 2011. 136 p. (in Russian).

10. Habriev R.U. Manual on experimental (preclinical) study of new pharmacological agents. Moscow, Medicine Publ., 2005. 832 p. (in Russian).

11. Cunningham A.I. A method of increased sensitivity for detecting single antibody-forming cells. Nature, 1965, vol. 207, no. 5001, pp. 1106–1107.

12. Hemagglutination reaction and antibody-dependent hemolysis. Antibodies. Methods. Ed. D. Ketti. Moscow, World Publ., 1991. 328 p. (in Russian).

13. Trukhacheva N.V Mathematical statistics in biomedical re-search using the package Statistica. Moscow, GEOTAR Media Publ., 2012. 384 p. (in Russian).

14. Grace M., Cutler D., Bordens R. Pegylated interferons in chronic hepatitis C. Recipe: scientific journal for pharma-cists and physicians, 2006, no. 6, pp. 118–128 (in Russian).

15. Foster G.R. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-α-2a and peginterferon-α-2b. Drugs, 2010, vol. 70, no. 2, pp. 147–165.

16. Thomas T., Foster G. Nanomedicines in The Treatment of Chronic Hepatitis C–Focus on Pegylated Interferon alpha-2a. Int. J. Nanomedicine, 2007, vol. 2, no. 1, pp. 19–24.

17. Goodbourn S., Didcock L., Randall R.E. Interferons: Cell signalling, immune modulation, antiviral responses and virus countermeasures. J. Gen. Virol., 2000, vol. 81, pp. 2341–2364